Short-Interval, Low-Dose [¹⁷⁷Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma

Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man with recurrent glioblastoma who was treated with 2 cycles of low-dose [177Lu]Lu-PSMA after exhausting all available treatment options in the state sector. Baseline imaging demonstrated intense PSMA signal in the known lesion, which was amenable to therapy. The prospect of [177Lu]Lu-PSMA-based therapy for glioblastoma is warranted going forward.